Stanley Laman Group Ltd. Decreases Stock Holdings in GSK PLC Sponsored ADR $GSK

Key Points

• Stanley Laman Group Ltd. has reduced its holdings in GSK PLC Sponsored ADR by 20.8%, now owning 97,844 shares worth approximately $3.76 million after selling 25,688 shares in the second quarter.
• GSK reported $1.23 earnings per share for the quarter, exceeding analysts' expectations, and announced a quarterly dividend of $0.4206 per share.
• Analysts currently have a consensus price target of $37.38 for GSK, with several brokerages upgrading their ratings in recent weeks.

Stanley Laman Group Ltd. reduced its position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 20.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,844 shares of the pharmaceutical company's stock after selling 25,688 shares during the period. Stanley Laman Group Ltd.'s holdings in GSK were worth $3,757,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of GSK. Dodge & Cox lifted its holdings in GSK by 14.9% in the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock worth $3,046,972,000 after buying an additional 10,210,921 shares during the period. Acadian Asset Management LLC raised its holdings in shares of GSK by 201.9% during the first quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company's stock valued at $154,244,000 after acquiring an additional 2,663,270 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in GSK in the first quarter worth $67,267,000. Miller Howard Investments Inc. NY boosted its holdings in GSK by 138.4% in the first quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock valued at $63,797,000 after acquiring an additional 955,891 shares in the last quarter. Finally, Clark Capital Management Group Inc. increased its position in GSK by 138.2% during the 1st quarter. Clark Capital Management Group Inc. now owns 1,565,735 shares of the pharmaceutical company's stock valued at $60,657,000 after purchasing an additional 908,284 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Up 0.3%

NYSE:GSK opened at $43.92 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm's 50-day moving average price is $40.97 and its 200-day moving average price is $39.03. The company has a market capitalization of $89.27 billion, a PE ratio of 20.33, a P/E/G ratio of 1.97 and a beta of 0.53. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $45.59.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter last year, the firm earned $0.43 earnings per share. The business's revenue for the quarter was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Shareholders of record on Friday, August 15th were issued a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Friday, August 15th. GSK's payout ratio is 78.24%.

Analysts Set New Price Targets

Several brokerages have commented on GSK. Weiss Ratings restated a "hold (c)" rating on shares of GSK in a report on Wednesday, October 8th. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Seven investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.